Search Result

Isoforms Recommended:	Na_v1.8

Results for "

Na(v)1.8

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Sodium Channel (56) Apoptosis (4) ATP Synthase (4) Autophagy (4) Drug Derivative (1) Environmental Pollutants (2) Ferroptosis (4) GABA Receptor (1) Glutathione Peroxidase (4) Isotope-Labeled Compounds (2) Mitophagy (4) NOD-like Receptor (NLR) (4) PINK1/Parkin (4) Potassium Channel (5) Reactive Oxygen Species (ROS) (3) Reference Standards (5) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (1) Cardiovascular Disease (8) Infection (4) Inflammation/Immunology (10) Neurological Disease (50)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Suzetrigine 5 Publications Verification VX-548	Sodium Channel	Neurological Disease
Suzetrigine (VX-548) is an orally active and highly selective *Na_V1.8* inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy .

DSP-2230 ANP-230	Sodium Channel	Cardiovascular Disease Neurological Disease
DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC₅₀s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain .

A-803467 3 Publications Verification	Sodium Channel	Neurological Disease Inflammation/Immunology Cancer
A-803467 is a potent and selective tetrodotoxin-resistant Na_v1.8 sodium channel blocker (IC₅₀=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .

ICA-121431 4 Publications Verification	Sodium Channel	Cardiovascular Disease
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Na_v) blocker, shows equipotent selectivity for human Na_v1.1 and Na_v1.3 subtypes with IC₅₀ values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Na_v1.2 (IC₅₀=240 nM) and 1,000 fold selectivity against Na_v1.4, Na_v1.6, and the TTX-resistant human Na_v1.5 and Na_v1.8 channels (IC₅₀s >10 μM).

Dexpramipexole dihydrochloride 2 Publications Verification (R)-Pramipexole dihydrochloride; R-(+)-Pramipexole dihydrochloride; KNS-760704 dihydrochloride	ATP Synthase Sodium Channel Glutathione Peroxidase NOD-like Receptor (NLR) Mitophagy Ferroptosis PINK1/Parkin Autophagy Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the *Na_v1.8* sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more .

PF-01247324 1 Publications Verification	Sodium Channel	Neurological Disease
PF-01247324 is a selective and orally bioavailable *Na_v1.8* channel blocker with an IC₅₀ of 196 nM for recombinant human Na_v1.8 channel.

Sodium Channel inhibitor 6	Sodium Channel	Neurological Disease
Sodium Channel inhibitor 6 (compound I) is a selective Na_v1.8 inhibitor that can be used in the study of neuropathic pain .

Bifenthrin 1 Publications Verification	Environmental Pollutants Sodium Channel	Neurological Disease
Bifenthrin is a synthetic pyrethroid insecticide. Bifenthrin prolongs the opening time of Nav1.8 sodium channels, leading to membrane depolarization and conductance block in the insect nervous system, thereby disrupting neural function. Bifenthrin was effective in inhibiting A. gambiae (LD₅₀=0.15 ng/mg) and C. quinquefasciatus (LD₅₀=0.16 ng/mg). Bifenthrin has good lethality against susceptible and resistant mosquitoes and is very effective in inhibiting blood sucking and can be developed as a mosquito-removal netting material .

A-887826	Sodium Channel	Neurological Disease
A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC₅₀ of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo .

VX-150 1 Publications Verification	Sodium Channel	Neurological Disease
VX-150 is an orally active, highly selective *Na_V1.8* inhibitor. VX-150 has the potential for various pain indications research .

PF-06305591	Sodium Channel	Neurological Disease
PF-06305591 is a potent and highly selective voltage gated sodium channel *NaV1.8* blocker, with an IC₅₀ of 15 nM. An excellent preclinical in vitro ADME and safety profile .

PF 04531083	Sodium Channel	Neurological Disease
PF 04531083 is an orally active and selective *Na_V1.8* blocker with an IC₅₀ of 0.7 μM. PF 04531083 is a blood-brain barrier (BBB) penetrant compound. PF 04531083 can be used for the research of respiratory system and neuropathic/inflammatory pain .

LTGO-33	Sodium Channel	Neurological Disease
LTGO-33 is a potent and selective voltage-gated sodium channel *NaV1.8* inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .

Nav1.8-IN-2	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-2 (compound 35A) is a *Nav1.8* voltage-gated sodium ion inhibitor with an IC₅₀ of 0.4 nM (HEK 293 cells). Nav1.8-IN-2 inhibits the activity of Nav1.8 voltage-gated sodium ion channels, mediates sodium ion influx in excitable cells, and is associated with the initiation and conduction of action potentials. Nav1.8-IN-2 can be used for research related to pain, cough, itching, etc .

Cyfluthrin	Environmental Pollutants Sodium Channel	Infection
Cyfluthrin is a type II pyrethroid and has effects on various insects. Cyfluthrin is a modulator of Nav_1.8 sodium channels by repetitive stimulation. Cyfluthrin can be applied in agriculture,veterinary, insecticide,pyrethroid and stored product .

3'-Methoxydaidzein	Sodium Channel	Neurological Disease
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC₅₀ of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .

Dexpramipexole 2 Publications Verification (R)-Pramipexole; R-(+)-Pramipexole; KNS-760704	PINK1/Parkin Glutathione Peroxidase Sodium Channel ATP Synthase NOD-like Receptor (NLR) Mitophagy Ferroptosis Autophagy Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Dexpramipexole ((R)-Pramipexole) is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the *Na_v1.8* sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more .

PF-04885614	Sodium Channel	Neurological Disease
PF-04885614 is a potent *NaV1.8* inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment .

ABBV-318	Sodium Channel	Neurological Disease
ABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC₅₀s of 2.8 μM and 3.8 μM for hNav1.7 and *hNav1.8*, respectively. ABBV-318 can be used for the research of pain .

E0199	Potassium Channel Sodium Channel	Neurological Disease
E0199 is a novel potent dual-target K_V7/Na_V modulator that activates the K_V7 channel (K_V7.2/7.3 (EC₅₀ = 12.78 nM), K_V7.2 (EC₅₀ = 0.50 μM), and K_V7.5 (EC₅₀ = 27.14 nM) channels) while simultaneously blocks the Na_V1.7 (IC₅₀ = 0.52 μM), Na_V1.8 (IC₅₀ = 0.24 μM), and Na_V1.9 (IC₅₀ = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research .

Nav1.8-IN-4	Sodium Channel	Infection
Nav1.8-IN-4 (compound 9a) is a *Nav1.8* channel inhibitor (IC₅₀=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases .

Nav1.8-IN-1	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-1 (Compound 31) is a potent inhibitor of Na(v)1.8 sodium channel. Nav1.8-IN-1 has the potential for the research of inflammatory and neuropathic pain .

(R)-Funapide (R)-TV 45070; (R)-XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
(R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel Nav1.7, *Nav1.8* and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

Heteropodatoxin-1 HpTx1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits Nav1.7 and activates Nav1.9 but does not affect Nav1.8 .

(S)-LTGO-33	Sodium Channel	Neurological Disease
(S)-LTGO-33 is a small molecule inhibitor of voltage-gated sodium channel NaV1.8. (S)-LTGO-33 can be used in the study of pain disorders .

PF-06305591 dihydrate	Sodium Channel	Neurological Disease
PF-06305591 dihydrate is a potent and highly selective voltage gated sodium channel *NaV1.8* blocker, with an IC₅₀ of 15 nM. An excellent preclinical in vitro ADME and safety profile .

Dexpramipexole-d3 dihydrochloride (R)-Pramipexole-d₃ dihydrochloride; R-(+)-Pramipexole-d₃ dihydrochloride; KNS-760704-d₃ dihydrochloride	Isotope-Labeled Compounds ATP Synthase Sodium Channel Glutathione Peroxidase NOD-like Receptor (NLR) Mitophagy Ferroptosis PINK1/Parkin Autophagy Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Dexpramipexole-d₃ ((R)-Pramipexole-d₃) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the *Na_v1.8* sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.

Nav1.8-IN-10	Sodium Channel	Neurological Disease
Nav1.8-IN-10 (Compound 6) is a *Nav1.8* channel inhibitor. When the concentration is 4 nM, the percentage blocking rate of Nav1.8 channel is 79.4%. Nav1.8-IN-10 can be used in the study of pain disorders .

Nav1.8-IN-18	Sodium Channel	Neurological Disease
Nav1.8-IN-19 (Compound 70) is a *Nav1.8* inhibitor.

Nav1.8-IN-13	Sodium Channel	Cardiovascular Disease
Nav1.8-IN-13 (compound 16) is a Nav1.8 inhibitor (pIC₅₀=7.9) .

Nav1.8-IN-19	Sodium Channel	Neurological Disease
Nav1.8-IN-19 (Compound 122) is a *Nav1.8* inhibitor with an IC₅₀ of 0.44 nM in HEK cells. Nav1.8-IN-19 can be used for the study of pain .

Nav1.8-IN-11	Sodium Channel	Neurological Disease
Nav1.8-IN-11 (Example 1) is a *Nav1.8* channel inhibitor with a IC₅₀ value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders .

Nav1.8-IN-15	Sodium Channel	Neurological Disease
Nav1.8-IN-15 (compound 6) is a potent *Nav1.8* inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain .

VSTx-3 κ-Theraphotoxin-Gr4a; Kappa-TRTX-Gr4a; Voltage sensor toxin 3; Peptide F	Others Potassium Channel	Neurological Disease
VSTx-3 is a K_V channel blocker. VSTx-3 is demonstrated to be a potent, TTX-sensitive sodium channel blocker and especially, a potent blocker of NaV1.8 channels (IC₅₀ 0.19 μM for hNaV1.3, 0.43 μM for hNaV1.7 and 0.77 μM for hNaV1.8 channels).

Nav1.8-IN-20	Sodium Channel	Neurological Disease
Nav1.8-IN-20 (Compound I) is an orally active and potent voltage-gated sodium channel Nav1.8 inhibitor with an IC₅₀ value of 14 nM. Nav1.8-IN-20 blocks the generation and conduction of action potentials in peripheral nociceptive neurons, exerting analgesic effects. Nav1.8-IN-20 is promising for research of various pain types such as acute pain, chronic pain, inflammatory pain, and neuropathic pain .

Nav1.8-IN-16	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-16 (Compound (R)-40) is an orally active and selective hNaV 1.8 inhibitor (IC₅₀: 5.9 nM). Nav1.8-IN-16 exerts analgesic effects by blocking NaV1.8 channels without significantly affecting other NaV subtypes or hERG channels. Nav1.8-IN-16 exhibits dose-dependent analgesic effects in postoperative pain and inflammatory pain models and can be used in pain-related research .

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

Nav1.8 modulator 1	Potassium Channel	Neurological Disease
Nav1.8 modulator 1 (compound 1) is a potent *Nav1.8* modulator. Nav1.8 modulator 1 has the potential for pain research .

Nav1.8-IN-6	Sodium Channel	Neurological Disease
Nav1.8-IN-6 (Compound 2j) is a novel pyridinone amide Nav1.8 channel inhibitor. The IC₅₀ values in the resting state and semi-activated state are 513.33 and 471.81 nM, respectively. Nav1.8-IN-6 has analgesic activity .

Scn10a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Scn10a Rat Pre-designed siRNA Set A contains three designed siRNAs for Scn10a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

A-887826 (Standard)	Sodium Channel Reference Standards	Neurological Disease
A-887826 (Standard) is the analytical standard of A-887826 (HY-100080). This product is intended for research and analytical applications. A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo .

Analgesic agent-2	Sodium Channel	Inflammation/Immunology
Analgesic agent-2 is a selective and orally active NaV1.8 Channel inhibitor, with an IC₅₀ of 50.18 nM in HEK293 cells stably expressing human NaV1.8 channel. Analgesic agent-2 has analgesic activity .

KGP-25	Sodium Channel GABA Receptor	Neurological Disease
KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting *Nav1.8* in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABA_A) in the central nervous system (CNS) for general anesthesia .

Scn10a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Scn10a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Scn10a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nav1.8-IN-7	Sodium Channel Potassium Channel	Neurological Disease
Nav1.8-IN-7 (Example 116) is a selective *Nav1.8* inhibitor. Nav1.8-IN-7 shows an inhibition of >50% with 100 nM for Nav1.8. Nav1.8-IN-7 inhibits hERG with an IC₅₀ of 15.6 μM. Nav1.8-IN-7 has the potential for pain research .

SCN10A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SCN10A Human Pre-designed siRNA Set A contains three designed siRNAs for SCN10A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.	Product Name	Target	Research Area

HY-P5786

Heteropodatoxin-1 HpTx1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits Nav1.7 and activates Nav1.9 but does not affect Nav1.8 .

HY-P5916

VSTx-3 κ-Theraphotoxin-Gr4a; Kappa-TRTX-Gr4a; Voltage sensor toxin 3; Peptide F	Peptides Potassium Channel	Neurological Disease
VSTx-3 is a K_V channel blocker. VSTx-3 is demonstrated to be a potent, TTX-sensitive sodium channel blocker and especially, a potent blocker of NaV1.8 channels (IC₅₀ 0.19 μM for hNaV1.3, 0.43 μM for hNaV1.7 and 0.77 μM for hNaV1.8 channels).

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

Cat. No.	Product Name	Chemical Structure

HY-17355BS

Dexpramipexole-d3 dihydrochloride

Dexpramipexole-d₃ ((R)-Pramipexole-d₃) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Na_v1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.

HY-B1837S

Cyfluthrin-d6
Cyfluthrin-d₆ (β-Cyfluthi-d₆) is deuterium labeled Cyfluthrin. Cyfluthrin is a type II pyrethroid and has effects on various insects. Cyfluthrin is a modulator of Nav_1.8 sodium channels by repetitive stimulation. Cyfluthrin can be applied in agriculture,veterinary, insecticide,pyrethroid and stored product .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P810721

	Nav1.8 Antibody FEPS2; Nav1.8; PN3; SNS; Na(v)1.8; SCNAA_HUMAN; SCN10A	IHC-P, IHC-F, IF-Tissue	Rat
	Nav1.8 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Nav1.8 .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS12521

Scn10a Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Scn10a Rat Pre-designed siRNA Set A contains three designed siRNAs for Scn10a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12520

Scn10a Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Scn10a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Scn10a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12519

SCN10A Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SCN10A Human Pre-designed siRNA Set A contains three designed siRNAs for SCN10A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks